

# Be alerted of new clinical trials in your space

## Cortellis Clinical Trials

This guide explains how to set up alerts to monitor updates on clinical trials in just a few clicks. Alerts are available at your fingertips from clinical trial results and individual reports in Cortellis Clinical Trials Intelligence.

When looking for clinical trials information, you only need to run your search **once** because next time Cortellis can rerun your search automatically and send you updates on competitor trials and any new trials in your field via email. This will help you keep an eye on trials recently completed, terminated or open for recruitment, for example.

All you need to do is set up an alert and then you can carry on with your daily activities while Cortellis monitors your results and sends you updates daily, weekly or monthly.


**Example:** Monitor new and existing phase 4 trials for psoriasis.

1. Run your search by indication, technology or mechanism of action.



A search bar with a dropdown menu set to 'All', the text 'psoriasis', and a blue 'Index' button with a magnifying glass icon.

2. Apply filters to narrow down your results.



The screenshot shows the filter interface for 'psoriasis'. On the left, a sidebar lists filter categories: Condition, Patient Segment, Biomarkers, Biomarker Type, Biomarker Role, and Drug Pipeline Interventions. The 'Condition' filter is expanded, showing a hierarchical tree. The 'Hierarchical List' radio button is selected. A callout box points to the tree with the text: 'Use hierarchical filters to include sub terms automatically.' The tree shows 'Dermatological disease (3120)' expanded, with 'Erythematousquamous skin disease (2815)' expanded further to show 'Psoriasis (2809)' and 'Parapsoriasis (2)' checked.

|  |   |
|--|---|
| Condition                                | <input type="checkbox"/> Select All/Deselect All              |
| Patient Segment                          | <input type="checkbox"/> Completed (184)                      |
| Biomarkers                               | <input checked="" type="checkbox"/> Recruiting (103)          |
| Biomarker Type                           | <input type="checkbox"/> Status not specified (52)            |
| Biomarker Role                           | <input checked="" type="checkbox"/> Not yet recruiting (48)   |
| Drug Pipeline Interventions              | <input type="checkbox"/> Terminated (29)                      |
| Drug Pipeline Highest Development Status | <input checked="" type="checkbox"/> No longer recruiting (21) |
| Site Name                                |   |
| Contact Name                             |   |
| Sponsors/Collaborators                   |   |
| Phase                                    |   |
| <b>Recruitment Status</b>                |   |

3. Click "Save and Alert" button -top right- from the results page.

< Back | Forward > Search Results Related Content Analyze **Save and Alert** Download

172 results found for index Search for the search term 'psoriasis' with filter(s) applied: Psoriasis; Phase 4 Clinical; "Planned"; No longer recruiting; Not yet recruiting; Recruiting

First Previous **1** 2 3 4 5 6 7 Next Last

| Report Type                   | Results  | Per page: 25 | Sort by: Last Change Date | Most Recent   | Order Columns  | View               |
|-------------------------------|--|--------------|---------------------------|---|--|--------------------|
| Show selected only            | <input checked="" type="checkbox"/> Title  |              | Filters: [1] Clear        | Filters: [0]  | Filters: [0]   | Filters: [4] Clear |
| Broker Research (61927)       | <input checked="" type="checkbox"/> <a href="#">Risankizumab Long-term Remission Study</a> |              | Psoriasis                 | Psoriasis - Subjects by disease severity; Psoriasis - Subjects with Plaque; Psoriasis/Psoriatias Vulgaris | Psoriasis - Assessment of Inflammatory & Oxidative Stress Markers - Serum immunoglobulins; Psoriasis - Assessment of Laboratory/Diagnostic Measures; Psoriasis - Assessment of Psoriasis | Recruiting         |
| <b>Clinical Trials (4231)</b> |  |              |                           |   |  | Phase 4 Clinical   |
| Companies (1370)              |  |              |                           |   |  |                    |
| Conferences (1944)            |  |              |                           |   |  |                    |

4. Select 'Alert on search query' and follow the instructions on the screen to set up your updates\* of interest and desired frequency.



Step 1
Step 2
Step 3
Step 4

**REASON FOR UPDATE**

The alerts notifications inform you about records that are new or that are removed from your search results set over time. To additionally include records that are updated, please select the 'Reasons for Update'.

**Alert updates...**

Select All

Protocol and Results

Recruitment Status



Alerts can also be set up from Clinical Trial reports by using the bell icon at the top right and following similar instructions.

< Back
Forward >
Clinical Trial Report
 Alert

Next

Risankizumab Long-term Remission Study

| Snapshot                  | Highlight <input type="checkbox"/> Search Terms & Synonyms                                       | < Previous | Next > |
|---------------------------|--|------------|--------|
| Protocol & Results        | SNAPSHOT <span style="float: right;">Results Available <b>No</b></span>                          |            |        |
| Subjects & Measurements   | Title Risankizumab Long-term Remission Study   |            |        |
| Registry Contacts & Sites | Scientific Title Immune Modification of Psoriasis by Selective IL-23 Blockade Using Risankizumab |            |        |
| Change History            | Identifiers NCT04630652; JKI-1011  |            |        |
| Sources                   | Condition Psoriasis <a href="#">View Epidemiology in IPD</a>                                     |            |        |
|                           | Disease Markers  |            |        |
|                           | Primary Interventions Biopsies alone <a href="#">risankizumab</a> alone                          |            |        |
|                           | Active Controls  |            |        |
|                           | Phase Phase 4 Clinical   |            |        |
|                           | Recruitment Status Recruiting  |            |        |
|                           | Reason for Trial Discontinuation   |            |        |
|                           | Sites <a href="#">1</a>  |            |        |
|                           | Sponsor Only <a href="#">Rockefeller University</a>  |            |        |

Here is a sample of an email alert sent when new and existing trials were announced or updated in conferences, clinical trial registries, press releases and other sources checked by Cortellis editors daily. Basic details of new trials and a summary of updates in existing trials are provided to help you analyze this new data quickly and direct links are also available to take you to the clinical trial report or set of results in Cortellis for further evaluation.

## CTI SEARCH ALERT

Your WEEKLY alert contains information that was updated on or after 26-Nov-2021

Name: psoriasis

### NEW - SINCE LAST ALERT

3 Reports were new to your results set in this time period.

[View in Cortellis](#)

#### Etanercept Therapy for Nails Psoriasis Monitoring With Noninvasive Imaging

- Conditions Psoriasis
- Phase Phase 4 Clinical
- Recruitment Status Recruiting
- Sponsor Companies OptiSkin Medical

### UPDATED - SINCE LAST ALERT

9 Reports were updated in this time period for the update types you are subscribed to.

[View in Cortellis](#)

#### Preparation and evaluation of Topical Rosuvastatin and Melatonin versus placebo in Patients with Mild to Moderate Plaque Psoriasis

| Date        | Event Type                   | Description  |
|-------------|------------------------------|--|
| 01-Dec-2021 | Recruitment Status Changed   | Recruiting to No longer recruiting   |
| 01-Dec-2021 | Eligibility Criteria updates | Inclusion Criteria - Added: "Patients 18 years and older Less than 10% body surface area (BSA)"<br>Removed: "Less than 10% body surface area (BSA);Patients 18 years and older;" |
| 01-Dec-2021 | Eligibility Criteria updates | Exclusion Criteria - Added: "Pregnancy Sensitivity to cream components"<br>Removed: "Pregnancy;Sensitivity to cream components;"   |

\*Depending on your type of subscription.

To find out what's included in your subscription, contact your Clarivate account manager or [LS Product Support](#)